PAVmed's Q1 Revenue Stalls at $22K, EPS Plunges to $(4.42)
PAVM is trading near its 52-week low of $6 (7.5% above the low).
Summary
PAVmed Inc. reported first-quarter 2026 revenue of just $22K and a diluted EPS of $(4.42), resulting in a net loss of $(6.99M). These results mark a significant decline from Q1 2025, which saw a net income of $17.7M and diluted EPS of $10.10. The minimal revenue and substantial loss reinforce the 'going concern' warning from the company's last 10-K and the need for 'highly dilutive' capital raises, as indicated by the recent DEF 14A filing on May 1st. The continued limited revenue momentum, particularly from Veris Health, and rising R&D expenses, highlight the company's ongoing cash burn and challenges in commercializing its products. Investors will be closely watching for further capital raising activities and any signs of accelerated commercialization or significant revenue growth from its product pipeline to address the persistent losses.
At the time of this announcement, PAVM was trading at $6.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.2M. The 52-week trading range was $6.00 to $28.44. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Wiseek News.